Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's

  • According to detailed dataEisai Limited ESALY and Biogen Inc's BIIB closely watched trial of an experimental Alzheimer's drug slowed cognitive decline but may carry a risk of side effects for certain patients.
  • Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 
  • 17.3% of patients had microhemorrhages in the brain— a symptom linked to two recent deaths of people receiving lecanemab in a follow-on study.
  • Treatment with lecanemab reduced clinical decline on the global cognitive and functional scale by 27% at 18 months, relative to the placebo, the trial's primary endpoint.
  • Two deaths— both from brain hemorrhages— have been reported among participants in a trial extension - a 65-year-old woman who received a type of medicine known as tissue plasminogen activator to clear blood clots after a stroke and an 87-year-old who was on the blood thinner Eliquis.
  • Eisai said the two deaths "cannot be attributed to lecanemab."
  • The FDA is slated to decide by January 6 whether to approve lecanemab under its accelerated review program.
  • Price Action: BIIB shares are up 6.05% at $308.97 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!